PathMaker Neurosystems is a clinical-stage company developing a breakthrough, non-invasive approach to the treatment of ALS (amyotrophic lateral sclerosis), an incurable neurodegenerative disease that damages motor neurons in the spinal cord and brain. Our pioneering approach uses multi-site direct current stimulation to modulate pathways and neurons involved in the ALS disease process. We can non-invasively reduce TDP-43 protein aggregation and spinal motor neuron hyperexcitability to increase survival and improve motor function. Our NIH-funded technology has been taken into two ALS clinical trials, having recently completed an early feasibility study that was funded by the Muscular Dystrophy Association, and we have started a second and larger ALS trial that is funded by U.S. Dept. of Defense. Our objective is to make ALS a livable disease, and we are seeking institutional investors who understand the terrible toll that ALS is taking on an increasing number of families.